Halozyme Therapeutics, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +39.1%
EBITDA: -10.8%
EBIT: +43.8%
EPS: -24.2%
Free cash flow: +34.7%
Operating cash flow: +34.4%

Forward estimates

Revenue: +26.7%
EBITDA: +131.1%
EPS: +220.0%

Three-year CAGR

Revenue: +28.4%
EBITDA: +22.0%
EBIT: +45.0%
Net income: +16.2%
EPS: +21.3%
Free cash flow: +39.9%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.